Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide. The post...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a...
Renowned hedge fund manager and Wall Street mogul Steve Cohen is showing his confidence in the psychedelic sector. Cohen’s hedge The post Cybin Rallies...
A new study published in the “ACS Pharmacology & Translational Science” journal has revealed that psychedelics such as psilocybin may combat stress...
In November 2022, Lusaris Therapeutics made news for its $60 million Series A round. Since then, there has been a curious silence from the company. We...
Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience. The post PurMinds Appoints Leading...
Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder....
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly. In fact, I’ve uncovered seven of the top...
Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024. The post Cybin Lands Key U.S....